Effect of Brimonidine Tartrate Ophthalmic Solution 0.15%... | NCT00413751

Studies
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751

Sponsor

Walter Reed Army Medical Center

Status

Completed

Last Update Posted

Dec 20, 2006Estimated

Enrollment

Phase

Not provided

Conditions

Healthy

Interventions

Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Dec 2006

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Not provided

Primary Completion Date

Not provided

Completion Date

Not provided

First Submitted Date

Dec 19, 2006

First Submission Date that Met QC Criteria

Dec 19, 2006

First Posted Date

Dec 20, 2006Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Dec 19, 2006

Last Update Posted Date

Dec 20, 2006Estimated

Description Module

Brief Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

Name	Type	Description	Arm Group Labels	Other Names
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)	Drug

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

Patients not meeting above stated age criteria
Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
History of serious ocular, neurological, cardiovascular disease
History of severe systemic disease
History of arrhythmias or high blood pressure
Patients currently taking any type of ocular or systemic medications except multivitamins.
Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

50 Years

Standard Ages

Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
KRAIG S. BOWER, MD	Walter Reed Army Medical Center	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Walter Reed Army Medical Center		Washington D.C.	District of Columbia	20307	United States

Condition Browse Module

MeSH Terms

ID	Term
D004172	Diplopia

Ancestor Terms

ID	Term
D014786	Vision Disorders
D012678	Sensation Disorders
D009461	Neurologic Manifestations
D009422	Nervous System Diseases

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D000068438	Brimonidine Tartrate

Ancestor Terms

ID	Term
D011810	Quinoxalines
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D006571	Heterocyclic Compounds

Browse Leaves

Not provided

Browse Branches

Not provided